NO933854L - Promedikamenter, deres fremstilling og anvendelse som legemiddel - Google Patents
Promedikamenter, deres fremstilling og anvendelse som legemiddelInfo
- Publication number
- NO933854L NO933854L NO933854A NO933854A NO933854L NO 933854 L NO933854 L NO 933854L NO 933854 A NO933854 A NO 933854A NO 933854 A NO933854 A NO 933854A NO 933854 L NO933854 L NO 933854L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- promotional
- drugs
- drug
- glycosyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4236237A DE4236237A1 (de) | 1992-10-27 | 1992-10-27 | Prodrugs, ihre Herstellung und Verwendung als Arzneimittel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO933854D0 NO933854D0 (no) | 1993-10-26 |
| NO933854L true NO933854L (no) | 1994-04-28 |
| NO311830B1 NO311830B1 (no) | 2002-02-04 |
Family
ID=6471460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19933854A NO311830B1 (no) | 1992-10-27 | 1993-10-26 | Promedikamenter, samt fremstilling derav |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US5955100A (no) |
| EP (1) | EP0595133B1 (no) |
| JP (1) | JP3841311B2 (no) |
| KR (1) | KR100297862B1 (no) |
| AT (1) | ATE494009T1 (no) |
| AU (1) | AU669218B2 (no) |
| CA (1) | CA2109259C (no) |
| DE (2) | DE4236237A1 (no) |
| IL (1) | IL107398A (no) |
| NO (1) | NO311830B1 (no) |
| NZ (1) | NZ250030A (no) |
| ZA (1) | ZA937951B (no) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4417865A1 (de) * | 1994-05-20 | 1995-11-23 | Behringwerke Ag | Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie |
| US5525606A (en) | 1994-08-01 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
| DE19512484A1 (de) * | 1995-04-04 | 1996-10-17 | Bayer Ag | Kohlenhydratmodifizierte Cytostatika |
| EP0751144B1 (en) | 1995-06-27 | 2004-10-06 | Pharmachemie B.V. | Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy |
| DE19524515A1 (de) * | 1995-07-05 | 1997-01-09 | Deutsches Krebsforsch | Saccharid-Konjugate |
| SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| GB9600471D0 (en) * | 1996-01-10 | 1996-03-13 | Univ London Pharmacy | Drug delivery system |
| ATE316799T1 (de) * | 1996-03-12 | 2006-02-15 | Sanofi Aventis Deutschland | Neuartige prodrugs für die therapie von tumoren und entzündlichen erkrankungen |
| EP0895784B1 (en) | 1996-04-15 | 2005-11-23 | Asahi Kasei Kabushiki Kaisha | Drug complexes comprising taxane compounds or steroids |
| AUPO203996A0 (en) * | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| DE19640207A1 (de) * | 1996-09-30 | 1998-04-02 | Bayer Ag | Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung) |
| CA2267328A1 (en) * | 1996-09-30 | 1998-04-09 | Bayer Aktiengesellschaft | Glycoconjugates from modified camptothecin derivates (20-o-linkage) |
| AU7201998A (en) * | 1997-05-06 | 1998-11-27 | Zhi Liu | Drug delivery system |
| ID23424A (id) * | 1997-05-14 | 2000-04-20 | Bayer Ag | Glikokonjugat dari 20(s)-kamptotesin |
| DE19720312A1 (de) * | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
| ATE272040T1 (de) | 1998-02-06 | 2004-08-15 | Univ Montfort | Durch hydroxylierung aktivierte medikamentvorstufen |
| GB2334256A (en) | 1998-02-12 | 1999-08-18 | Univ Montfort | Hydroxylation activated prodrugs |
| WO1999040944A2 (en) * | 1998-02-12 | 1999-08-19 | De Montfort University | Hydroxylation activated drug release |
| AU5925399A (en) * | 1998-09-16 | 2000-04-03 | Oncopharmaceutical, Inc. | Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent |
| US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| FR2791679B1 (fr) * | 1999-03-31 | 2003-04-11 | Fabre Pierre Dermo Cosmetique | Bioprecurseurs aptes a liberer un derive retinoique par mise a profit de l'activite enzymatique de la surface cutanee et compositions pharmaceutiques et/ou cosmetiques |
| NZ515134A (en) | 1999-05-04 | 2004-01-30 | Strakan Ltd | Androgen glycosides and androgenic activity thereof |
| DE19925810A1 (de) * | 1999-06-07 | 2000-12-14 | Paz Arzneimittelentwicklung | Anwendung von Verapamil und Verapamilderivaten zur Herstellung von Arzneimitteln mit Glucuronidase hemmender Wirkung |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| DE10027887A1 (de) | 2000-05-31 | 2001-12-13 | Jenapharm Gmbh | Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| US6638312B2 (en) | 2000-08-04 | 2003-10-28 | Depuy Orthopaedics, Inc. | Reinforced small intestinal submucosa (SIS) |
| US7220824B1 (en) | 2000-08-28 | 2007-05-22 | Bayer Aktiengesellschaft | Integrin-mediated drug targeting |
| AU2001292993A1 (en) * | 2000-09-25 | 2002-04-08 | Pro-Pharmaceuticals, Inc. | Compositions for reducing side effects in chemotherapeutic treatments |
| US6436386B1 (en) | 2000-11-14 | 2002-08-20 | Shearwater Corporation | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
| US7829074B2 (en) | 2001-10-18 | 2010-11-09 | Nektar Therapeutics | Hydroxypatite-targeting poly(ethylene glycol) and related polymers |
| US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
| EP1238678A1 (en) * | 2001-03-08 | 2002-09-11 | Bayer Aktiengesellschaft | Enzyme-activated cytostatic conjugates with integrin ligands |
| US7819918B2 (en) | 2001-07-16 | 2010-10-26 | Depuy Products, Inc. | Implantable tissue repair device |
| US7163563B2 (en) | 2001-07-16 | 2007-01-16 | Depuy Products, Inc. | Unitary surgical device and method |
| US8025896B2 (en) | 2001-07-16 | 2011-09-27 | Depuy Products, Inc. | Porous extracellular matrix scaffold and method |
| US8092529B2 (en) | 2001-07-16 | 2012-01-10 | Depuy Products, Inc. | Meniscus regeneration device |
| WO2003007787A2 (en) | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Cartilage repair and regeneration device and method |
| US7201917B2 (en) | 2001-07-16 | 2007-04-10 | Depuy Products, Inc. | Porous delivery scaffold and method |
| US20060014697A1 (en) | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
| US7169752B2 (en) | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| JP4527978B2 (ja) * | 2001-12-03 | 2010-08-18 | ウニベルジテートスクリーニクム シャリテー デア フンボルト−ウニベルジテート ツー ベルリン テクノロジー トランスファーステラ | ポドフィロトキシン |
| AU2002366303B2 (en) * | 2001-12-17 | 2007-09-20 | University College Cardiff Consultants Limited | Enzymatic cleavable reagents for specific delivery to disease sites |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| WO2004000863A1 (ja) * | 2002-06-20 | 2003-12-31 | Nippon Suisan Kaisha, Ltd. | プロドラッグ、その医薬としての使用、およびその製法 |
| AU2003285200A1 (en) * | 2002-11-09 | 2004-06-03 | Nobex Corporation | Modified carbamate-containing prodrugs and methods of synthesizing same |
| DE10256982A1 (de) | 2002-12-05 | 2004-06-24 | Schering Ag | Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung |
| EP1581218A1 (en) * | 2002-12-05 | 2005-10-05 | Schering AG | Epothilone analogs for site specific delivery in the treatment of proliferative diseases |
| US8133881B2 (en) | 2003-01-13 | 2012-03-13 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
| WO2004064734A2 (en) * | 2003-01-17 | 2004-08-05 | Threshold Pharmaceuticals, Inc. | Combination therapies for the treatment of cancer |
| WO2004082629A2 (en) | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
| US7160867B2 (en) | 2003-05-16 | 2007-01-09 | Isotechnika, Inc. | Rapamycin carbohydrate derivatives |
| US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| WO2005034856A2 (en) * | 2003-09-05 | 2005-04-21 | The Regents Of The University Of Colorado | Targeted drug-formaldehyde conjugates and methods of making and using the same |
| US20050053664A1 (en) | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| US7569233B2 (en) | 2004-05-04 | 2009-08-04 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorbable scaffolds |
| US7534780B2 (en) | 2004-05-21 | 2009-05-19 | Bayer Schering Pharma Aktiengesellschaft | Estradiol prodrugs |
| US7825096B2 (en) * | 2004-09-08 | 2010-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs |
| EP1804823A4 (en) | 2004-09-29 | 2010-06-09 | Amr Technology Inc | NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS |
| JP2008514701A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | シクロスポリンアルキン類似体およびそれらの薬学的使用 |
| US7361636B2 (en) | 2004-10-06 | 2008-04-22 | Amr Technology, Inc. | Cyclosporin alkynes and their utility as pharmaceutical agents |
| US7354627B2 (en) | 2004-12-22 | 2008-04-08 | Depuy Products, Inc. | Method for organizing the assembly of collagen fibers and compositions formed therefrom |
| TW200631586A (en) * | 2005-03-08 | 2006-09-16 | Phytohealth Corp | A method for preparing a pharmaceutical compound by way of magnetic carbon nanocapsules |
| JP4896959B2 (ja) * | 2005-03-30 | 2012-03-14 | サラダックス バイオメディカル インク. | ドキソルビシン免疫測定法 |
| US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| WO2007149827A2 (en) * | 2006-06-20 | 2007-12-27 | Janssen Pharmaceutica, N.V. | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
| US20080031866A1 (en) * | 2006-06-20 | 2008-02-07 | Eichenbaum Gary M | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
| US7871440B2 (en) | 2006-12-11 | 2011-01-18 | Depuy Products, Inc. | Unitary surgical device and method |
| US7792651B2 (en) * | 2007-04-26 | 2010-09-07 | General Electric Company | Methods and systems for computing gear modifications |
| WO2008153394A2 (en) * | 2007-06-14 | 2008-12-18 | Academisch Medisch Centrum | Novel anti-inflammatory pro-drugs |
| JP5823125B2 (ja) | 2007-10-23 | 2015-11-25 | ウェルズ ファーゴ バンク ナショナル アソシエイション | ヒドロキシアパタイト標的化多腕ポリマーならびに、このポリマーから作られるコンジュゲート |
| CN101970042A (zh) * | 2008-02-25 | 2011-02-09 | 眼门药品公司 | 经由离子电渗法增强递送治疗药物至眼部组织 |
| US20100028416A1 (en) * | 2008-07-30 | 2010-02-04 | Nitto Denko Corporation | Drug carriers |
| WO2011056957A2 (en) * | 2009-11-06 | 2011-05-12 | Chelsea Therapeutics, Inc. | Enzyme inhibiting compounds |
| KR101253399B1 (ko) | 2010-10-26 | 2013-04-11 | 영남대학교 산학협력단 | 아포지단백질 a-i 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형 |
| EP2468741A1 (en) | 2010-12-16 | 2012-06-27 | Bel/Novamann International s.r.o. | Novel quercetin derivatives, their preparation, pharmaceutical compositions containing them and their use |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
| HUE032891T2 (hu) | 2012-12-17 | 2017-11-28 | Parion Sciences Inc | Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére |
| EP2931712B8 (en) | 2012-12-17 | 2018-05-23 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| US10464955B2 (en) | 2014-02-28 | 2019-11-05 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
| EP3319936B1 (en) | 2015-07-12 | 2025-12-17 | Hangzhou Dac Biotech Co., Ltd. | Bridge linkers for conjugation of cell-binding molecules |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| KR20220147721A (ko) | 2016-11-14 | 2022-11-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
| JP7333335B2 (ja) * | 2017-12-21 | 2023-08-24 | ファーマシティクス ビー. ブイ. | 化合物、その医薬上許容可能な塩、医薬組成物、および薬の経口の生物学的利用能の増加方法 |
| IL282748B2 (en) | 2018-11-05 | 2025-07-01 | Bayer Pharma AG | Cytostatic conjugates with integrin ligands |
| EP4413006A1 (en) | 2021-10-04 | 2024-08-14 | Vincerx Pharma GmbH | Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders |
| EP4412655A1 (en) | 2021-10-04 | 2024-08-14 | Vincerx Pharma GmbH | Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder |
| KR20240089138A (ko) | 2021-10-04 | 2024-06-20 | 빈서스 파마 게엠베하 | 과증식성 장애의 치료, 예방, 또는 관리를 위한 화합물, 약제학적 조성물, 및 방법 |
| WO2025047983A1 (ja) * | 2023-08-31 | 2025-03-06 | 国立大学法人 東京大学 | がん特異的酵素活性を標的とした新規プロドラッグ型抗がん剤 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1541436A (en) * | 1976-02-02 | 1979-02-28 | Searle & Co | Immunological materials |
| US4279992A (en) * | 1978-03-13 | 1981-07-21 | Miles Laboratories, Inc. | Specific binding assay employing an enzyme-cleavable substrate as label |
| US4481195A (en) * | 1978-10-13 | 1984-11-06 | Adolf Schwimmer | Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals |
| US4265885A (en) * | 1978-10-25 | 1981-05-05 | Farmitalia Carlo Erba S.P.A. | Anthracyclines containing branched-chain amino-deoxy sugars |
| WO1981001145A1 (en) * | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| DK406686D0 (da) * | 1986-08-26 | 1986-08-26 | Hans Bundgaard | Carboxylsyrederivater |
| US5434247A (en) * | 1986-10-10 | 1995-07-18 | Board Of Regents, The University Of Texas System | Peptides for inducing monocyte cytotoxicity in diagnostics |
| GB8705477D0 (en) * | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| IL106992A (en) * | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| DE3842836A1 (de) * | 1988-12-20 | 1990-06-21 | Behringwerke Ag | Rhodomycine mit einer modifizierten kohlenhydrat-einheit |
| DK24089D0 (da) * | 1989-01-20 | 1989-01-20 | Hans Bundgaard | Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups |
| US5433955A (en) * | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
| DE3924655A1 (de) * | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Anthracyclin-derivate |
| DE3928659A1 (de) * | 1989-08-30 | 1991-03-07 | Bayer Ag | Ketophosphamidglycoside, verfahren zu ihrer herstellung sowie ihre verwendung als pharmazeutische wirkstoffe |
| DE3935016A1 (de) * | 1989-10-20 | 1991-04-25 | Behringwerke Ag | Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1991009831A1 (en) * | 1989-12-26 | 1991-07-11 | Nova Pharmaceutical Corporation | Prodrug anhydrides of asprin, indomethacin and ibuprofen, their preparation, compositions, and anti-inflammatory method of use |
| DE4002888A1 (de) * | 1990-02-01 | 1991-08-08 | Behringwerke Ag | Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten |
| US5137877B1 (en) * | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
| GB9017024D0 (en) * | 1990-08-03 | 1990-09-19 | Erba Carlo Spa | New linker for bioactive agents |
| WO1992004048A2 (en) * | 1990-08-30 | 1992-03-19 | The Biomembrane Institute | Inhibition of metastasis potential and invasiveness by oligosaccharides or oligosaccharide antigens or antibodies |
| AU649275B2 (en) * | 1990-11-06 | 1994-05-19 | Bristol-Myers Squibb Company | Prodrugs for beta-lactamase and uses thereof |
| FR2676058B1 (fr) * | 1991-04-30 | 1994-02-25 | Hoechst Lab | Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers. |
-
1992
- 1992-10-27 DE DE4236237A patent/DE4236237A1/de not_active Withdrawn
-
1993
- 1993-10-15 DE DE59310399T patent/DE59310399D1/de not_active Expired - Lifetime
- 1993-10-15 EP EP93116702A patent/EP0595133B1/de not_active Expired - Lifetime
- 1993-10-15 AT AT93116702T patent/ATE494009T1/de active
- 1993-10-22 NZ NZ250030A patent/NZ250030A/en not_active IP Right Cessation
- 1993-10-25 IL IL10739893A patent/IL107398A/en not_active IP Right Cessation
- 1993-10-26 AU AU50225/93A patent/AU669218B2/en not_active Expired
- 1993-10-26 CA CA002109259A patent/CA2109259C/en not_active Expired - Lifetime
- 1993-10-26 NO NO19933854A patent/NO311830B1/no not_active IP Right Cessation
- 1993-10-26 ZA ZA937951A patent/ZA937951B/xx unknown
- 1993-10-26 JP JP26697693A patent/JP3841311B2/ja not_active Expired - Lifetime
- 1993-10-27 KR KR1019930022473A patent/KR100297862B1/ko not_active Expired - Lifetime
-
1995
- 1995-05-24 US US08/449,021 patent/US5955100A/en not_active Expired - Lifetime
-
1997
- 1997-05-20 US US08/859,084 patent/US6146658A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU5022593A (en) | 1994-05-12 |
| CA2109259A1 (en) | 1994-04-28 |
| ZA937951B (en) | 1995-07-05 |
| IL107398A (en) | 2001-01-28 |
| DE59310399D1 (de) | 2011-02-17 |
| EP0595133B1 (de) | 2011-01-05 |
| NO933854D0 (no) | 1993-10-26 |
| EP0595133A2 (de) | 1994-05-04 |
| US5955100A (en) | 1999-09-21 |
| IL107398A0 (en) | 1994-01-25 |
| CA2109259C (en) | 2005-05-24 |
| KR940008685A (ko) | 1994-05-16 |
| US6146658A (en) | 2000-11-14 |
| NO311830B1 (no) | 2002-02-04 |
| JPH06293665A (ja) | 1994-10-21 |
| NZ250030A (en) | 1994-12-22 |
| JP3841311B2 (ja) | 2006-11-01 |
| EP0595133A3 (de) | 1998-11-04 |
| AU669218B2 (en) | 1996-05-30 |
| KR100297862B1 (ko) | 2001-10-24 |
| DE4236237A1 (de) | 1994-04-28 |
| ATE494009T1 (de) | 2011-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO933854L (no) | Promedikamenter, deres fremstilling og anvendelse som legemiddel | |
| DE68911473D1 (de) | Arzneimittelformulierungen. | |
| PT83872A (de) | Arzneimittel | |
| KR950700754A (ko) | 신규의 약물(novel medicament) | |
| FI953533L (fi) | Transdermaalinen terapeuttinen järjestelmä, jossa on galantamiinia vaikuttavana aineena | |
| AR002982A1 (es) | Benzonitrilos y benzofluoruros, un procedimiento para prepararlos, su empleo para preparar médicamentos, un médicamento hecho a base de estos compuestos, las preparaciónes farmacéuticas que los contienen y un procedimiento para obtener estas preparaciónes farmacéuticas. | |
| NO934706D0 (no) | Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner | |
| ATE173627T1 (de) | Medizinische zusammensetzung | |
| NO923721D0 (no) | 4-desoksy-4-epipodophyllotoxin-derivat eller farmasoeytiskakseptabelt salt derav | |
| FI950165A7 (fi) | Ihon läpäisevä terapeuttinen järjestelmä, jossa vaikuttavana aineena o n 17-beta-estradioli (vedetön) | |
| NO892764L (no) | Medikamentell administreringsform for droevtyggere. | |
| DE3679156D1 (de) | Teilbare kapsel. | |
| IT8722501A0 (it) | Formulazioni farmaceutiche per somministrazione transdermica. | |
| DK0511800T3 (da) | Farmaceutisk formulering indeholdende dirithromycin | |
| DK0804927T3 (da) | Multiantioxidantholdigt medikament | |
| DE69318153D1 (de) | Antihypercholesterämisch-wirksame verbindungen, pharmazeutische präparate und verwendungen davon | |
| DK0579939T3 (da) | Phospholipidderivater | |
| ATA124091A (de) | Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz | |
| DE3761561D1 (de) | N,n-bis-(4-fluorophenyl)carbamoylacetohydroxamsaeure und diese enthaltende pharmazeutische zusammensetzungen. | |
| NO923720D0 (no) | Tienocyklopentanonoksimetere, fremstilling derav og farmasoeytiske blandinger som inneholder dem | |
| EP0729950A4 (en) | ANTI-HIV MEDICINAL PRODUCTS | |
| DE3773322D1 (de) | Pharmazeutische zubereitungen mit heilender aktivitaet. | |
| IT8819541A0 (it) | Composizione farmaceutica per somministrazione nasale. | |
| IT8922215A0 (it) | Formulazioni farmaceutiche. | |
| ATE78405T1 (de) | Pharmazeutische zusammensetzung, enthaltend piperidinalkanolderivate. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |